INMB INmune Bio: Company Book Value

INmune Bio, Inc. (INMB) is developing advanced methods to combat oncology and dementia by neutralizing the TNF protein to halt neurodegeneration. The technology stack is supplemented by automated data analysis systems and robotic compound screening, which accelerates the launch of new products. The current metric stands at 0.02. This chart of the company's market valuation demonstrates the impact of the patent portfolio and the results of XPro Phase 2 trials on investment attractiveness.

Book value is calculated as the difference between total assets and liabilities, reflecting the company's actual equity without accounting for market volatility. For INmune Bio, Inc. (INMB), the current book value demonstrates the financial stability necessary to fund XPro1595 trials and develop the oncology pipeline, allowing investors to assess the actual material basis for the growth of the biotechnology business.